Trial
NCT00395967
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Multiple Myeloma
Intervention
G-CSF plus plerixafor
Why stopped
Enrollment terminated in 2005 to focus on Phase 3 study enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-05-01